These were the findings of the Post Marketing Surveillance (PMS), study of Favipiravir (FabiFlu) on over 1000 patients
The study was conducted in patients with mild to moderate COVID-19
BALflu is approved by DCGI for emergency use for the treatment of COVID-19
The product patent has been already filed under fast track approval
Favipiravir is close to Remdesivir, Remdesivir is used to treat moderate to severe cases while Favipiravir is used to treat mild to moderate cases
The tablets will be manufactured and marketed under Vivimed’s brand name “Favulous” across India
Multiples is the first private equity (PE) investor in the company
_256_384.jpg)
The council has also reduced the GST to 5 per cent on a few more Covid-19 medicines
Domestic business was up 41.9% YoY and 27.7% QoQ
Availability of drugs is being monitored by implementing a three-pronged strategy of supply chain management, demand side management, and affordability.
Subscribe To Our Newsletter & Stay Updated
